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Abstract
Introduction: In an animal model of acromegaly (PEPCK-hGH transgenic mice), low systemic levels of
ghrelin have been observed compared with normal mice. We hypothesized that systemic circulating
ghrelin levels are also decreased in humans with active acromegaly and that the contribution of cen-
tral ghrelin production to systemic ghrelin levels is minimal.
Objectives: The aim of the present study was to investigate, in two subjects with active acromegaly,
whether there are differences between systemic ghrelin levels and ghrelin concentrations in the pet-
rosal sinus.
Design: We measured systemic and central ghrelin levels in these two acromegalic patients by bilateral
simultaneous inferior petrosal sinus sampling. Central and systemic blood samples were drawn before
and 1, 5, 10, 15 and 20 min after stimulation with GH-releasing hormone (GHRH). Ghrelin was
measured with a commercially available radioimmunoassay.
Results: In one acromegalic subject, the baseline systemic and central ghrelin levels were within the
same range as in two non-acromegalic obese subjects. No gradient could be observed between central
and systemic ghrelin concentrations. Stimulation with GHRH did not change the ghrelin concen-
trations in this patient. In the other acromegalic subject, the systemic ghrelin levels were also in
the same range as in two non-acromegalic obese subjects. However, in this subject, baseline ghrelin
concentrations in the right inferior petrosal vein were considerably lower than the systemic ghrelin
concentrations, indicating a peripheral over central gradient. Administration of GHRH induced a sig-
nificant rise in central ghrelin concentrations in the right inferior petrosal vein. Ghrelin levels in the
left inferior petrosal vein and systemic ghrelin levels were in the normal range and GHRH stimulation
did not change these concentrations.
Conclusions: The absence of a central over peripheral ghrelin gradient in these two acromegalics indi-
cated that circulating ghrelin is mainly produced peripherally. Circulating systemic ghrelin levels were
not decreased in these two subjects with active acromegaly.
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Introduction
For years, regulation of growth hormone (GH) release
was considered to be the net result of stimulation by
GH-releasisng hormone (GHRH) and inhibition by
somatostatin. The discovery of ghrelin, a 28 amino
acid peptide, which induces GH release in vivo and in
vitro, has added another regulatory mechanism to
this system (1). Ghrelin is a more potent GH secreta-
gogue than GHRH (2). The observation that ghrelin
and GHRH act synergistically suggests that these pep-
tides have, at least partially, different mechanisms of
action. However, the feedback mechanisms of ghrelin
are still unknown (2). Ghrelin is produced in the
stomach and is also expressed in the hypothalamic
arcuate nucleus (1). Korbonits and co-workers detected
ghrelin mRNA expression in normal human pituitary
tissue as well as in pituitary adenomas, including somato-
troph adenomas. This strongly suggests that ghrelin is
produced in the pituitary gland, where it may influence
the release of GH in an autocrine or paracrine manner
(3, 4).
In a murine model of acromegaly (PEPCK-hGH
transgenic mice), low levels of systemic ghrelin have
been observed as compared with controls (5). We
hypothesized that systemic ghrelin levels are also
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decreased in humans with active acromegaly and that
the contribution of central ghrelin production to the
systemic ghrelin levels is minimal. The aim of the pre-
sent study was to investigate whether there are differ-
ences between systemic ghrelin levels and ghrelin
concentrations in the petrosal sinus in human acro-
megaly. Therefore, we measured systemic and central
ghrelin levels in two acromegalic patients, who under-
went bilateral simultaneous inferior petrosal sinus
sampling (BSIPSS) because of diagnostic reasons.
Patients and methods
Patients and controls
Two males with active acromegaly were studied and
two obese subjects without acromegaly were studied
as controls. However, the body mass index (BMI) of
the obese subjects (31.0 and 32.1 kg/m2) was lower
that the BMI of the two acromegalics (39.2 and
34.7 kg/m2). Both acromegalic patients (56 and 51
years) presented with classical acromegalic complaints.
Physical examination revealed typical acromegalic fea-
tures. Serum insulin-like growth factor-I (IGF-I) levels
were significantly elevated: 105 nmol/l in patient 1
and 65 nmol/l in patient 2 (normal range for age and
gender: 11–35 nmol/l). Fasting insulin concentrations
in these two acromegalics were 14.9 and 6.4 mU/l
respectively. The diagnosis of acromegaly was con-
firmed in both patients by an abnormal GH response
to an oral glucose tolerance load (GH .2.5mg/l). As
these acromegalic subjects initially showed no clear
pituitary abnormalities on magnetic resonance imaging
(MRI) at the referring hospital, we performed BSIPSS in
both subjects, at their request, to locate an adenoma.
However, in the first acromegalic patient, a somato-
troph pituitary adenoma of 7 mm at the right side of
the pituitary could be detected by MRI at follow-up.
He showed normalization in serum IGF-I after initiation
of long-acting somatostatin analogue therapy as pri-
mary treatment. Also, in the second acromegalic
patient, a centrally located somatotroph microadenoma
was found with a diameter of 1 cm during follow-up
MRI. He successfully underwent trans-sphenoidal
surgery.
Two patients with centripetal obesity (one 70-year-
old male and one 42-year-old female) underwent
BSIPSS because of suspected Cushing’s disease as part
of the diagnostic work-up. Fasting insulin concen-
trations in these two non-acromegalic obese subjects
were 29.9 and 34.6 mU/l respectively. However, after
extensive testing, Cushing’s syndrome could be
excluded in both subjects. Cushingoid obesity was diag-
nosed in the male subject while polycystic ovary syn-
drome was diagnosed in the female subject. We
therefore decided to use both of them as controls for
this study. The study was performed according to the
rules of the hospital medical ethics committee. All sub-
jects entered the study after informed consent.
BSIPSS
After an overnight fast, BSIPSS was performed via
bilateral femoral vein puncture. In both inferior petro-
sal sinuses, a 4 French multipurpose catheter (Cordis
Europe, Roden, The Netherlands) was installed and
catheter position was checked by injecting small
amounts of iodinated non-ionic contrast (6). Central
and peripheral blood samples were drawn before and
1, 5, 10, 15 and 20 min after stimulation. Control sub-
jects were stimulated with 1mg/kg body weight cortico-
trophin-releasing hormone (CRH; Ferring, Hoofddorp,
The Netherlands). The acromegalic patients were
stimulated with recombinant human GHRH (Ferring)
as an intravenous bolus injection (1mg/kg).
Biochemical measurements
All blood samples were collected on ice and allowed to
coagulate for 30 min. Subsequently, serum was separ-
ated by centrifugation and frozen at 220 8C. Ghrelin
was measured with a commercially available radio-
immunoassay (Phoenix Pharmaceuticals Inc., Belmont,
CA, USA; intra-assay coefficient of variation (CV) 5.3%;
interassay CV 13.6%). This radioimmunoassay uses
125I-labelled bioactive ghrelin as a tracer molecule
and a polyclonal antibody raised in rabbits against
full-length octanoylated human ghrelin. In accordance
with the manual no extraction procedure was per-
formed for the ghrelin assay. In a previous study in
ten healthy volunteers, we observed mean peripheral
circulating ghrelin levels of 84 pmol/l (range: 35–
132) (7). We used these values to compare the data
of the present study.
GH was measured with a commercially available
radioimmunoassay (CIS bio international, Gif-sur
Yvette Cedex, France; intra-assay CV 2.8%; interassay
4.4%).
IGF-I was measured with a commercially available
immunoradiometric assay (Diagnostic Systems Labora-
tories Inc., Webster, TX, USA; intra-assay CV 4.9%;
interassay CV 5.1%).
Results
Baseline values
In the control subjects, the baseline peripheral and cen-
tral ghrelin levels were within the normal peripheral
ghrelin concentration range, as previously reported
(7, 8). No clear gradient could be observed between
systemic and central ghrelin concentrations in the con-
trols (Fig. 1a). In the first acromegalic subject, however,
the systemic ghrelin level was well within the normal
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range. The central baseline ghrelin concentration in
this patient was considerably lower in the right inferior
petrosal vein as compared with the systemic concen-
tration, indicating a peripheral over central gradient.
The baseline sample taken from the left inferior petrosal
vein had to be discarded, because of problems in the
positioning of the tip of the catheter in the hypoplastic
left petrosal sinus. However, repositioning enabled us to
measure ghrelin in the left petrosal sinus during GHRH
stimulation (Fig. 1b). In the second acromegalic
patient, the baseline peripheral and central ghrelin
levels were within the normal range. Also, in this acro-
megalic subject, no clear differences could be observed
between peripheral and central ghrelin concentrations
(Fig. 1c).
Central and peripheral ghrelin levels after
stimulation
No change in central or peripheral ghrelin concen-
trations were observed after CRH administration in
both controls (Fig. 1a). As might be expected, both
controls showed a significant increase in adrenocortico-
trophin (ACTH) after CRH administration in both petro-
sal sinuses without lateralization (data not shown).
In the first acromegalic subject, administration of
GHRH induced a significant rise in ghrelin concen-
trations in the right inferior petrosal sinus (Fig. 1b).
On this side, central ghrelin rose from 19 pmol/l at
baseline to a peak level of 104 pmol/l, 20 min after
GHRH administration. Concomitantly, right-sided cen-
tral GH levels increased from 9 ng/ml to 746 ng/ml,
20 min after stimulation (Table 1). No baseline ghrelin
level in the left inferior petrosal sinus was available,
because of the problems already mentioned in the posi-
tioning of the tip of the catheter. After repositioning,
ghrelin levels in the left inferior petrosal sinus after
GHRH stimulation showed no increase and remained
about 21 pmol/l. Baseline central left-sided GH levels
were not available (see above). Central left-sided GH
levels rose to 418 ng/ml after GHRH stimulation
(Table 1).
Figure 1 (a) Ghrelin concentration in left (B) and right (V) pituitary
and in systemic (peripheral) (*) blood at baseline and 1, 5, 10, 15
and 20 min after stimulation with CRH in control patient 1. Ghrelin
concentration in left (A) and right (S) pituitary and in peripheral
(+) blood at baseline and 1, 5, 10, 15 and 20 min after stimulation
with CRH in control patient 2. (b) Ghrelin concentration in left (B)
and right (V) pituitary and in systemic (peripheral) (*) blood at
baseline and 1, 5, 10, 15 and 20 min after stimulation with GHRH
in acromegalic patient 1. (c) Ghrelin concentration in left (B) and
right (V) pituitary and in systemic (peripheral) (*) blood at baseline
and 1, 5, 10, 15 and 20 min after stimulation with GHRH in acro-
megalic patient 2.
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In the second acromegalic subject, central and
peripheral ghrelin levels remained unchanged after
GHRH stimulation (Fig. 1c). After GHRH adminis-
tration, peripheral GH concentration increased from
1 ng/ml to 31 ng/ml in patient 1 and from 6 ng/ml to
16 ng/ml in patient 2 (Table 1). Peripheral ghrelin
levels did not change after GHRH stimulation in these
two subjects.
Discussion
Wright and co-workers (5) previously observed that
systemic ghrelin levels were lower in an animal model
of acromegaly. We therefore expected to find lowered
systemic ghrelin levels in acromegalic subjects in
whom no clear pituitary abnormalities in the MRI of
the referring hospital were seen. We therefore per-
formed BSIPSS in both subjects, at their request, to
locate an adenoma. However, in the first acromegalic
patient a somatotroph pituitary adenoma of 7 mm at
the right side of the pituitary could be detected on an
MRI at follow-up and, during follow-up MRI, in the
second patient a centrally located somatotroph micro-
adenoma was found with a diameter of 1 cm.
The baseline results of our study did not show differ-
ences in systemic ghrelin levels between the two acro-
megalics and the obese control subjects. Although
Tscho¨p et al. (8) have reported that systemic ghrelin
levels are lower in obese versus lean subjects, our acro-
megalics showed even higher BMI values than the
obese ‘controls’, which might indicate that they could
serve as proper controls in this study.
Systemic ghrelin levels in the acromegalic patients
were not stimulated by GHRH. Our observations
suggest that systemic ghrelin levels are not clearly
decreased in human acromegaly despite high systemic
GH concentrations. Surprisingly, in the first acromega-
lic patient we observed a peripheral over central gradi-
ent of more than 1.0. The cause of this gradient of more
than 1.0 is not clear. Systemic samples were drawn
from the femoral vein, which is not considered to be a
major source of ghrelin. In addition, an active central
nervous system clearance of systemic ghrelin is not
very likely. More interesting was the lateralization of
pituitary ghrelin levels after GHRH stimulation in one
acromegalic subject. A clear stimulation at the right
side could be detected. At follow-up, an MRI revealed
an ipsilateral pituitary tumor. This indicates that in
this acromegalic patient no clear central overproduc-
tion of ghrelin was present and that ghrelin could still
be stimulated by exogenous GHRH. In the second acro-
megalic patient, a centrally located somatotroph micro-
adenoma was also found during follow-up pituitary
MRI. In this patient, there was neither a gradient
between baseline peripheral and central ghrelin levels
nor a gradient between peripheral and central ghrelin
levels after GHRH stimulation, suggesting that central
ghrelin production does not substantially contribute
to the systemic ghrelin level. In our normal subjects,
systemic ghrelin levels also seem to be the result of
peripheral ghrelin production only, as no central over
peripheral gradient could be detected.
In the two healthy controls, CRH administration was
not able to modify either central or systemic ghrelin
levels. Ghrelin stimulates not only GH secretion, but
also ACTH and prolactin secretion (2). In the two con-
trol subjects, CRH administration significantly
increased both central and systemic ACTH concen-
trations. No direct feedback of ACTH could be found
on central and systemic ghrelin levels.
In conclusion, our study suggests that, at least in
some patients with active acromegaly, circulating sys-
temic ghrelin levels are not decreased. The absence of
a central over peripheral ghrelin gradient in acromega-
lics and controls indicates that central ghrelin pro-
duction does not substantially contribute to the
systemic ghrelin level.
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